Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Wedbush Initiates Coverage On Immunome with Outperform Rating, Announces Price Target of $12

Author: Benzinga Newsdesk | December 19, 2023 08:40am
Wedbush analyst David Nierengarten initiates coverage on Immunome (NASDAQ:IMNM) with a Outperform rating and announces Price Target of $12.

Posted In: IMNM

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist